| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 53 | 9.3x | 17.8x | Around median | |
Growth | 18 | -12.7% | 7.1% | Bottom tier | |
Quality | 44 | -4.4% | 4.5% | Around median | |
Safety | 53 | — | 2.6x | Around median | |
Capital Return | 78 | — | 2.12% | Top tier | |
Momentum | 29 | -26.6% | 2.9% | Bottom tier | |
Sentiment | 82 | 4 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
HUTCHMED (China) Limited is an oncology pharmaceutical company that relies on a mix of product sales in China, revenue associated with the commercialization of FRUZAQLA outside China through Takeda, and research and development revenue, upfront payments, and contractual milestones. Total oncology revenue reached $286 million in fiscal year 2025, including $71 million from upfront payments and research and development milestone revenue, while the company recorded $366 million in ex-China in-market sales of FRUZAQLA, up 26%, with availability in more than 38 countries.
According to EDGAR filings, total revenue declined to $548.5 million in fiscal year 2025 from $630.2 million in fiscal year 2024 and $838.0 million in fiscal year 2023. Gross profit fell to $212.2 million from $281.3 million, representing a gross margin of approximately 38.7% versus about 44.6% in fiscal year 2024. In contrast, net income rose to $456.9 million and earnings per share to 0.52, but $416 million of the profit came from a one-time gain on the sale of SHPL; management confirmed that the core operations remained profitable after excluding it.
Fiscal year 2025 Q4 results showed a clear divergence across markets and products. ELUNATE in-market sales in China declined 13% during fiscal year 2025 due to a weak first half and a reduction in the sales team, before growing 33% in the second half, while ORPATHYS and SULANDA together represented 11% of total in-market sales and remained under competitive pressure. At the same time, the company spent $148 million on research and development and ended fiscal year 2025 with approximately $1.4 billion in liquidity to support ATTC programs and potential licensing and acquisition opportunities, without announcing a specific acquisition target.
The analysts' average price target is $13.8, within a narrow range of $13.6 to $14, versus a 52-week share-price range of $9.77 to $18.3; the average target is therefore approximately 24.6% below the top of the 52-week range. The consensus is “Buy,” but the absence of a comparable price-to-earnings ratio and the dependence of fiscal year 2025 net income on the $416 million gain from the sale of SHPL require the stock to be assessed based on recurring operating earnings and clinical portfolio outcomes rather than reported net income alone.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
HUTCHMED is guiding for oncology revenue of between $330 million and $450 million in fiscal year 2026, compared with oncology revenue of $286 million in fiscal year 2025. The plan is based on the expansion of FRUZAQLA outside China, growth in Chinese products, and the addition of new indications such as RCC for ELUNATE. Management said the midpoint of the guidance range represents approximately 36% growth, with licensing agreements potentially contributing part of the increase toward the upper end.
Net income reached $456.9 million and earnings per share were 0.52 in fiscal year 2025, compared with $37.7 million and earnings per share of 0.04 in fiscal year 2024. Of fiscal year 2025 net income, $416 million came from a one-time gain on the sale of SHPL. Management confirmed that the core operations remained profitable after excluding this gain, but the reported figure does not fully represent recurring operating profit.
FRUZAQLA generated ex-China in-market sales of $366 million in fiscal year 2025, up 26%, and reached more than 38 countries. Growth accelerated in the second half, supported by launches in Portugal, Belgium, and South Korea, in addition to performance in Japan and some European markets. In contrast, the product faced pressure in the United States related to the Medicare Part D redesign, so continued growth also depends on expansion outside the U.S. market.
Automated analysis for informational purposes only — not investment advice.
The company expects the SAFFRON readout in mid-2026 and the SANOVO readout in the second half of 2026 or early 2027, both related to the development of savolitinib. The sovleplenib application for the treatment of ITP in China is also undergoing Priority Review after being resubmitted, while the savolitinib application for MET-amplified gastric cancer was accepted for Priority Review. On the ATTC platform, A251 and 580 entered clinical development, and the company expects 830 to enter global Phase 1 during 2026.
The ATTC platform was designed to combine the precision delivery of antibodies with the efficacy of targeted inhibitors, with the aim of delivering the payload directly to the tumor and reducing off-tumor toxicity. A251 consists of a PI3K and PIKK inhibitor linked to a HER2 antibody, and showed preclinical HER2-dependent activity with an IC50 concentration of approximately 0.2 nanomolar and a bystander effect on nearby cells. The candidate began a global Phase 1 study in China and the United States in patients with HER2-expressing solid tumors, but the company has not specified a final date for the data readout.
Liquidity reached approximately $1.4 billion at the end of fiscal year 2025, compared with research and development spending of $148 million during the same year. Management intends to increase research investment in the following years to an annual level of between $250 million and $300 million as the ATTC programs and Phase 3 trials advance. The company says it will balance this spending with commercial income to maintain sustained profitability, and it is also evaluating licensing and acquisition opportunities without announcing a specific target.
